Positive preliminary data shows that SENS-401 has a clinically significant effect
on preservation of residual hearing after cochlear implantation in all patients
adults treated so far.
• On June 19, Sensorion announced the presence of SENS-401 in the perilymph of treated patients
with SENS-401. Analyzes today indicate a preservation of 21 dB of hearing
residual of patients treated with SENS-401 at 500 Hz, compared to the control group, six
weeks after cochlear implantation.